CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathwa (Q47898008)
Jump to navigation
Jump to search
scientific article published on 31 July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathwa |
scientific article published on 31 July 2013 |
Statements
1 reference
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathwa (English)
1 reference
1 reference
1 reference
R C Prins
1 reference
R T Burke
1 reference
M M Loriaux
1 reference
S E Spurgeon
1 reference
31 July 2013
1 reference
1 reference
27
1 reference
10
1 reference
2094-2096
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference